세계 CAR-T 세포 치료 시장 규모는 2024년 43억 2,000만 달러에 달했고, 2032년에 242억 9,000만 달러에 이를 것으로 예측됩니다. 예측 기간인 2025년-2032년에 CAGR 24.11%를 나타낼 것으로 예상됩니다. 키메라 항원 수용체 CAR-T 세포 치료 시장은 세계에서 혈액암 유병률이 높아지고, 보다 신뢰성 높은 치료법을 발견하기 위한 활동이 확대되고 있기 때문에 큰 성장을 보이고 있습니다. 승인된 CAR-T 세포 치료는 백혈병, 림프종, 골수종과 같은 여러 유형의 혈액암에 큰 효능을 보이기 때문에 이러한 치료법에 대한 주목도가 크게 높아지고 시장 성장을 더욱 뒷받침하고 있습니다.
새로운 CAR-T 세포 치료에 대한 승인 증가와 임상시험 중 견고한 제품 파이프라인도 시장 확대에 중요한 역할을 하고 있습니다. 시장 진출기업 간 시장 접근성과 수익성 향상을 목적으로 한 제휴 및 파트너십은 과거 기간에 시장의 중요한 촉진요인이었음이 입증되었으며 예측 기간도 비슷한 결과가 예측됩니다. 게다가 규제 준수와 새로운 치료법 승인 프로세스의 간소화를 위한 제조업체의 활동이 증가함에 따라 이 시장에 대한 투자자들의 관심이 커지고 시장 성장이 기대됩니다.
이 보고서는 세계 CAR-T 세포 치료 시장에 대한 조사 분석을 통해 시장 규모와 예측, 시장 역학, 주요 기업 현황 등을 제공합니다.
Global CAR T-cell therapy market is projected to witness a CAGR of 24.11% during the forecast period 2025-2032, growing from USD 4.32 billion in 2024 to USD 24.29 billion in 2032. The chimeric antigen receptor (CAR) T-cell therapy market is witnessing significant growth due to the growing prevalence of hematological malignancies across the globe and efforts to find more reliable treatments for them. The significant efficacy of approved CAR T-cell therapies against several types of hematological malignancies like leukemia, lymphoma, and myeloma has significantly drawn attention toward these therapies, further fueling the market's growth.
An increasing number of approvals for new CAR T-cell therapies and a robust pipeline of products undergoing clinical trials are also playing a crucial role in the market's expansion. Collaborations and partnerships among the market participants to increase market access and profitability have proven to be a significant driver for the market during the historical period and are expected to generate similar results over the forecast period. Additionally, regulatory compliance and increasing efforts of the manufacturers for streamlining the approval process of new therapies coupled with the increasing interest of investors in this market seem promising for market's growth.
Increasing Prevalence of Cancer Boosts Market Demand
As the number of cases of cancer increases, the requirement for advanced therapeutic solutions for effectively treating and managing the condition is also on the rise. Hematological malignancies such as leukemia and lymphoma require innovative treatment solutions such as CAR T-cell therapies as they have shown significant success rates for such conditions. Thus, healthcare institutes across the globe are increasingly focusing on introducing such therapies for treating cancer patients. For instance, in January 2025, Safdarjung Hospital in Delhi, India used a CAR T-cell therapy procedure on a patient suffering from non-Hodgkin lymphoma. This marks the first time CAR T-cell therapy has been used in a central government hospital in India for treating cancer that failed to respond to conventional treatment methods.
Rising Approvals from Regulatory Bodies Supports Market Expansion
The increase in regulatory approvals is playing a crucial role in the growth of the market by allowing wider patient access, encouraging research and development, and increasing investor confidence. As different regulatory bodies recognize the potential of CAR T-cell therapies, they are focusing on streamlining and fast tracking the approval processes, boosting the commercial adoption of the therapies and positively influencing the market's expansion.
For instance, in May 2024, the Food and Drug Administration provided accelerated approval to Juno Therapeutics, Inc. for Breyanzi (lisocabtagene maraleucel) for adults with refractory or relapsed follicular lymphoma, that have received prior systemic therapy. The application was granted orphan drug designation and priority review by the regulatory body. The safety and efficacy of the therapy were evaluated in TRANSCEND-FL (NCT04245839), in an open-label, single-arm, Phase 2, multicenter trial in adults with refractory or relapsed follicular lymphoma.
Lymphoma Accounts for Significant Share of the Market
Due to the high prevalence of the condition and the effective nature of the therapy for treating the disease, the segment holds a significant share in the market. According to the estimates of the American Cancer Society, non-Hodgkin lymphoma accounts for approximately 4% of the cancer cases in America. In order to combat the growing threat of the condition, various regulatory and governing bodies across the globe are increasingly focusing on providing approval to CAR T-cell therapies for treating lymphoma. For instance, in February 2025, the National Institute for Health and Care Excellence (NICE) granted approval to a CAR T-cell therapy for adults with large B-cell lymphoma. The treatment significantly improves survival outcomes and delays the progression of the disease. Lisocabtagene maraleucel is recommended for patients whose cancer has relapsed or is refractory within the first year of the first-line chemoimmunotherapy.
North America Region Holds Major Market Share
With high investment in research and development activities, technological advancements by key players, and presence of advanced healthcare infrastructure, North American countries, including the United States and Canada, are expected to dominate the market with the highest value share. The supportive government initiatives for managing blood-related diseases are also supporting the growth of the market in the region.
Meanwhile, the Asia-Pacific is expected to witness the highest growth over the forecast period. Countries such as Japan, China, and South Korea are significantly investing in CAR T-cell therapy research. The strong market presence of leading players also supporting the market's expansion in the region. Additionally, different governments in the region are recognizing the potential of the CAR T-cell therapies and are increasingly funding research projects to encourage their development.
Future Market Scenario (2025 - 2032F)
The market is expected to witness significant growth in the coming years due to advancements in clinical research, expanded clinical indications of therapy, and rising cases of cancer across the globe. The American Cancer Society estimates that the number of cases of cancer will reach 35 million globally by 2050. Thus, the reliance on CAR T-cell therapy is anticipated to increase significantly over the forecast period.
Meanwhile, innovations aimed at simplifying the manufacturing process and reducing the costs associated with CAR T-cell therapy are expected to improve their accessibility. To support such innovations, leading healthcare and biotech companies are increasingly focusing on developing collaborations. Companies are also focusing on automating production processes for streamlining and standardizing CAR T-cell therapy manufacturing processes, with the goal of reducing processing time and labor cost.
Additionally, CAR T-cell therapies are being increasingly studies in combination with other therapeutic solutions to improve their durability and effectiveness, especially in the cases where traditional treatment options have failed to yield significant results over the patient population. Thus, propelling the utilization of CAR T-cell therapies and providing lucrative growth opportunities for the market.
Key Players Landscape and Outlook
The leading players of the market are significantly focusing on research and development activities and supporting the market's growth and expansion. The companies are also focusing on securing fundings to advanced CAT T therapy trials. For instance, in February 2025, Hemogenyx Pharmaceuticals LLC secured funding to advance its CAR-T therapy trials, aimed at next-generation treatments for acute myeloid leukemia (AML). CAR-T therapy involves the engineering of a patient's T-cells to destroy cancer cells, potentially a more effective and less toxic treatment than traditional chemotherapy. The funding will be used to fund Phase I clinical trials, which will test the safety and preliminary efficacy of this groundbreaking therapy. This development is a significant achievement for Hemogenyx in its pursuit of improving the prognosis of AML patients, who currently have low survival rates. Hemogenyx expects that CAR-T therapy will have a significant impact on the treatment and survival of AML patients.
Similarly, in February 2025, Anixa Biosciences, Inc. announced that it, along with Moffitt Cancer Center, had dosed the third cohort of patients in their Phase 1 clinical trial of their novel CAR-T therapy for recurrent ovarian cancer. After a 30-day confirmation period has passed, the fourth cohort will start with an increase in dose. Anixa's CAR-T technology is designed to target the follicle-stimulating hormone receptor (FSHR), expressed preferentially on ovarian cells and tumor vasculature. The trial (NCT05316129) investigates safety and efficacy in women with recurrent ovarian cancer who have undergone numerous previous treatments. A new protocol amendment allows eligible patients to receive a second dose and enrollment to include rare ovarian cancer subtypes. Such efforts are expected to bolster the availability of advanced treatment technologies and provide lucrative growth opportunities for the market.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.